BiotechTube

Voclosporin

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Focal Segmental Glomerulosclerosis

Conditions

Focal Segmental Glomerulosclerosis

Trial Timeline

Jun 21, 2018 → May 19, 2020

NCT ID
NCT03598036

About Voclosporin

Voclosporin is a phase 2 stage product being developed by Aurinia Pharmaceuticals for Focal Segmental Glomerulosclerosis. The current trial status is terminated. This product is registered under clinical trial identifier NCT03598036. Target conditions include Focal Segmental Glomerulosclerosis.

What happened to similar drugs?

4 of 10 similar drugs in Focal Segmental Glomerulosclerosis were approved

Approved (4) Terminated (1) Active (6)
✅OnabotulinumtoxinA 145 UNT [Botox]AbbVieApproved
✅DapagliflozinAstraZenecaApproved
✅Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, ZonisamidePfizerApproved
✅Levetiracetam + Carbamazepine + LamotrigineUCBApproved
🔄Empasiprubart + IVIG (Intravenous Immunoglobulin)ArgenxPhase 3
🔄Gadoxetic Acid Disodium (Primovist, BAY86-4873)BayerPhase 3
🔄XEN1101 + PlaceboXenon PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
9
Novelty
0
Community
0

Clinical Trials (5)

NCT IDPhaseStatus
NCT05962788Phase 3Terminated
NCT03598036Phase 2Terminated
NCT02949999Phase 1Completed
NCT02949973Phase 2Completed
NCT00258713Phase 3Completed

Competing Products

20 competing products in Focal Segmental Glomerulosclerosis

See all competitors
ProductCompanyStageHype Score
OnabotulinumtoxinA 145 UNT [Botox]AbbVieApproved
35
DapagliflozinAstraZenecaApproved
43
Enfuvirtide + Tenofovir-EmtricitabineRochePhase 2
35
CCX140-BAmgenPhase 2
27
PF-06730512PfizerPhase 2
27
Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, ZonisamidePfizerApproved
43
VX-147Vertex PharmaceuticalsPhase 2
35
VX-147Vertex PharmaceuticalsPhase 1
29
IXPVertex PharmaceuticalsPhase 1
29
fresolimumab + fresolimumab + PlaceboSanofiPhase 2
35
GC1008 + GC1008 + GC1008 + GC1008SanofiPhase 1
29
frexalimab + brivekimig + rilzabrutinib + placeboSanofiPhase 2
42
VivaglobinCSLPhase 2
35
UCB0942UCBPhase 2
27
Levetiracetam + Carbamazepine + LamotrigineUCBApproved
43
Brivaracetam + BrivaracetamUCBPhase 2
35
LacosamideUCBPhase 2
27
UCB0942 + UCB0942 + PlaceboUCBPhase 2
35
LacosamideUCBPre-clinical
26
ARGX-117ArgenxPhase 2
36